Introduction

Hemolytic Uremic Syndrome (HUS) is a serious clinical condition characterized by platelet consumption, hemolysis, and multi-organ hypoxic / ischemic damage (particularly kidney and brain). Its incidence varies considerably due to geographical and climatic elements but in Western countries it is the main cause of acute renal failure in children. Although the disease is more common in children, adults can also be affected.

Technical features

To date, there are no specific treatments for STEC haemolytic uremic syndrome and patient management is based only on supportive measures: red blood cell transfusions, antihypertensive therapy, dialysis, anticonvulsant drugs, respiratory and resuscitation treatments. Fenoldopam, a dopaminergic drug known for its vasodilatory properties, can be used in the treatment of haemolytic uremic syndrome from diagnosis of the disease to recovery of renal function. Researchers at the Ospedale Policlinico di Milano have documented that, in HUS, Fenoldopam significantly reduces renal vascular resistance without modifying systemic hemodynamics, thus increasing organ perfusion. This specific action results in the reduction of hypoxic / ischemic damage to the kidney.

Possible Applications

• Treatment of HUS at onset to reduce kidney damage;
• Prevention and treatment of AKI.

Advantages

• The proposed treatment aims at improving kidney perfusion in HUS and in other renal diseases with reduced organ perfusion.